136 related articles for article (PubMed ID: 19900446)
1. Cell-type specific gene expression signature in liver underlies response to interferon therapy in chronic hepatitis C infection.
Chen L; Borozan I; Sun J; Guindi M; Fischer S; Feld J; Anand N; Heathcote J; Edwards AM; McGilvray ID
Gastroenterology; 2010 Mar; 138(3):1123-33.e1-3. PubMed ID: 19900446
[TBL] [Abstract][Full Text] [Related]
2. Interferon-γ-stimulated genes, but not USP18, are expressed in livers of patients with acute hepatitis C.
Dill MT; Makowska Z; Duong FHT; Merkofer F; Filipowicz M; Baumert TF; Tornillo L; Terracciano L; Heim MH
Gastroenterology; 2012 Sep; 143(3):777-786.e6. PubMed ID: 22677194
[TBL] [Abstract][Full Text] [Related]
3. Interferon-induced gene expression is a stronger predictor of treatment response than IL28B genotype in patients with hepatitis C.
Dill MT; Duong FH; Vogt JE; Bibert S; Bochud PY; Terracciano L; Papassotiropoulos A; Roth V; Heim MH
Gastroenterology; 2011 Mar; 140(3):1021-31. PubMed ID: 21111740
[TBL] [Abstract][Full Text] [Related]
4. Hepatic ISG expression is associated with genetic variation in interleukin 28B and the outcome of IFN therapy for chronic hepatitis C.
Honda M; Sakai A; Yamashita T; Nakamoto Y; Mizukoshi E; Sakai Y; Yamashita T; Nakamura M; Shirasaki T; Horimoto K; Tanaka Y; Tokunaga K; Mizokami M; Kaneko S;
Gastroenterology; 2010 Aug; 139(2):499-509. PubMed ID: 20434452
[TBL] [Abstract][Full Text] [Related]
5. Liver gene expression signature to predict response to pegylated interferon plus ribavirin combination therapy in patients with chronic hepatitis C.
Asselah T; Bieche I; Narguet S; Sabbagh A; Laurendeau I; Ripault MP; Boyer N; Martinot-Peignoux M; Valla D; Vidaud M; Marcellin P
Gut; 2008 Apr; 57(4):516-24. PubMed ID: 17895355
[TBL] [Abstract][Full Text] [Related]
6. An intrahepatic transcriptional signature of enhanced immune activity predicts response to peginterferon in chronic hepatitis B.
Jansen L; de Niet A; Makowska Z; Dill MT; van Dort KA; Terpstra V; Bart Takkenberg R; Janssen HL; Heim MH; Kootstra NA; Reesink HW
Liver Int; 2015 Jul; 35(7):1824-32. PubMed ID: 25533046
[TBL] [Abstract][Full Text] [Related]
7. Hepcidin/ferroportin expression levels involve efficacy of pegylated-interferon plus ribavirin in hepatitis C virus-infected liver.
Kohjima M; Yoshimoto T; Enjoji M; Fukushima N; Fukuizumi K; Nakamura T; Kurokawa M; Fujimori N; Sasaki Y; Shimonaka Y; Murata Y; Koyama S; Kawabe K; Haraguchi K; Sumida Y; Harada N; Kato M; Kotoh K; Nakamuta M
World J Gastroenterol; 2015 Mar; 21(11):3291-9. PubMed ID: 25805936
[TBL] [Abstract][Full Text] [Related]
8. Suppressor of cytokine signaling 3 (SOCS3) expression and hepatitis C virus-related chronic hepatitis: Insulin resistance and response to antiviral therapy.
Persico M; Capasso M; Persico E; Svelto M; Russo R; Spano D; Crocè L; La Mura V; Moschella F; Masutti F; Torella R; Tiribelli C; Iolascon A
Hepatology; 2007 Oct; 46(4):1009-15. PubMed ID: 17668875
[TBL] [Abstract][Full Text] [Related]
9. Chronic hepatitis C genotype 6 responds better to pegylated interferon and ribavirin combination therapy than genotype 1.
Tsang OT; Zee JS; Chan JM; Li RS; Kan YM; Li FT; Lo FH; Chow DA; Cheung KW; Chan KH; Yeung YW; Ng FH; Li MK; Kwan WK; Lai TS
J Gastroenterol Hepatol; 2010 Apr; 25(4):766-71. PubMed ID: 20492332
[TBL] [Abstract][Full Text] [Related]
10. Hepatic gene expression discriminates responders and nonresponders in treatment of chronic hepatitis C viral infection.
Chen L; Borozan I; Feld J; Sun J; Tannis LL; Coltescu C; Heathcote J; Edwards AM; McGilvray ID
Gastroenterology; 2005 May; 128(5):1437-44. PubMed ID: 15887125
[TBL] [Abstract][Full Text] [Related]
11. Innate immune tolerance and the role of kupffer cells in differential responses to interferon therapy among patients with HCV genotype 1 infection.
Lau DT; Negash A; Chen J; Crochet N; Sinha M; Zhang Y; Guedj J; Holder S; Saito T; Lemon SM; Luxon BA; Perelson AS; Gale M
Gastroenterology; 2013 Feb; 144(2):402-413.e12. PubMed ID: 23123437
[TBL] [Abstract][Full Text] [Related]
12. Natural killer cell receptor and HLA-C gene polymorphisms among patients with hepatitis C: a comparison between sustained virological responders and non-responders.
Carneiro VL; Lemaire DC; Bendicho MT; Souza SL; Cavalcante LN; Angelo AL; Freire SM; Mendes CM; Santana N; Lyra LG; Lyra AC
Liver Int; 2010 Apr; 30(4):567-73. PubMed ID: 20456039
[TBL] [Abstract][Full Text] [Related]
13. Hepatic iron accumulation is associated with disease progression and resistance to interferon/ribavirin combination therapy in chronic hepatitis C.
Fujita N; Sugimoto R; Urawa N; Araki J; Mifuji R; Yamamoto M; Horiike S; Tanaka H; Iwasa M; Kobayashi Y; Adachi Y; Kaito M
J Gastroenterol Hepatol; 2007 Nov; 22(11):1886-93. PubMed ID: 17914965
[TBL] [Abstract][Full Text] [Related]
14. Insulin resistance predicts response to peginterferon-alpha/ribavirin combination therapy in chronic hepatitis C patients.
Dai CY; Huang JF; Hsieh MY; Hou NJ; Lin ZY; Chen SC; Hsieh MY; Wang LY; Chang WY; Chuang WL; Yu ML
J Hepatol; 2009 Apr; 50(4):712-8. PubMed ID: 19231011
[TBL] [Abstract][Full Text] [Related]
15. Non-response to antiviral therapy is associated with obesity and increased hepatic expression of suppressor of cytokine signalling 3 (SOCS-3) in patients with chronic hepatitis C, viral genotype 1.
Walsh MJ; Jonsson JR; Richardson MM; Lipka GM; Purdie DM; Clouston AD; Powell EE
Gut; 2006 Apr; 55(4):529-35. PubMed ID: 16299039
[TBL] [Abstract][Full Text] [Related]
16. Changes in gene expression during pegylated interferon and ribavirin therapy of chronic hepatitis C virus distinguish responders from nonresponders to antiviral therapy.
Taylor MW; Tsukahara T; Brodsky L; Schaley J; Sanda C; Stephens MJ; McClintick JN; Edenberg HJ; Li L; Tavis JE; Howell C; Belle SH
J Virol; 2007 Apr; 81(7):3391-401. PubMed ID: 17267482
[TBL] [Abstract][Full Text] [Related]
17. Association of pretreatment serum interferon gamma inducible protein 10 levels with sustained virological response to peginterferon plus ribavirin therapy in genotype 1 infected patients with chronic hepatitis C.
Diago M; Castellano G; García-Samaniego J; Pérez C; Fernández I; Romero M; Iacono OL; García-Monzón C
Gut; 2006 Mar; 55(3):374-9. PubMed ID: 16150856
[TBL] [Abstract][Full Text] [Related]
18. Liver protein profiling in chronic hepatitis C: identification of potential predictive markers for interferon therapy outcome.
Perdomo AB; Ciccosanti F; Iacono OL; Angeletti C; Corazzari M; Daniele N; Testa A; Pisa R; Ippolito G; Antonucci G; Fimia GM; Piacentini M
J Proteome Res; 2012 Feb; 11(2):717-27. PubMed ID: 22098443
[TBL] [Abstract][Full Text] [Related]
19. Impact of liver steatosis on the antiviral response in the hepatitis C virus-associated chronic hepatitis.
Soresi M; Tripi S; Franco V; Giannitrapani L; Alessandri A; Rappa F; Vuturo O; Montalto G
Liver Int; 2006 Nov; 26(9):1119-25. PubMed ID: 17032413
[TBL] [Abstract][Full Text] [Related]
20. Cell-type specific interferon stimulated gene staining in liver underlies response to interferon therapy in chronic HBV infected patients.
Zhu Y; Qin B; Xiao C; Lu X; Chen L
Dig Dis Sci; 2012 Sep; 57(9):2355-61. PubMed ID: 22585383
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
